Stock Groups

Moderna predicts boost to sales from COVID-19 turning endemic -Breaking

by Mike Robinson

[ad_1]

© Reuters. FILEPHOTO: In this illustration, a vial and sryinge can be seen in front a Moderna logo. It was taken Jan 11, 2021. REUTERS/Dado Ruvic/Illustration/File Photo/File Photo

(Reuters] Moderna Inc Thursday forecast higher sales for the second quarter of 2018 as COVID-19 becomes an endemic flu-like illness. People are encouraged to have regular vaccines.

From $18.5 billion, the company anticipates sales of $19 billion this year. It also stated that talks are ongoing to order vaccines in 2023.

Moderna (NASDAQ) said that the vaccine’s value will be lower during the pandemic, and it would change its pricing strategy when COVID-19 starts subsiding.

It also stated that it is working on a “bivalent” vaccine booster, which includes an Omicron-specific booster as well as its COVID-19 original vaccine.

Moderna currently has one product in the marketplace. This is to support its research and development activities as it seeks to develop a wide range of vaccines and treatment using mRNA technology.

Moderna’s shares fell almost 4% during trading, amid weakness in the wider markets.

Moderna projected $18.5 billion sales from its vaccine with $3.5 billion of options. The company now anticipates that it will have $3 billion worth of options.

Disclaimer: Fusion MediaWe remind you that this site does not contain accurate or real-time data. CFDs include stocks, indexes and futures. Prices are provided not by the exchanges. Market makers provide them. Therefore, prices can be inaccurate and differ from actual market prices. These prices should not be used for trading. Fusion Media does not accept any liability for trade losses you may incur due to the use of these data.

Fusion MediaFusion Media and anyone associated with it will not assume any responsibility for losses or damages arising from the use of this information. This includes data including charts and buy/sell signal signals. You should be aware of all the potential risks and expenses associated with trading in the financial market. It is among the most dangerous investment types.

[ad_2]